XTL Biopharmaceuticals Ltd(NASDAQ:XTLB) 
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome....
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.11
H 1.40
L 0.92
C 0.99
V 18,871
10EMA 0.99
20EMA 0.99
60EMA 0.99
120EMA 0.99
250EMA 0.99